Investigador nanociencia, nanotherapia
Vla*** ***** (XX años)
Juan de la Cierva Incorporación-Post-doc en CNB
Independent University of Madrid
Fuenlabrada,
Madrid
Este candidato esta dispuesto a trasladarse
|
Experiencia
Juan de la Cierva Incorporación-Post-doc
CNB
abr 2019
-
Actualmente
My current projects involve the elucidation of the effect of metallic nanoparticles on immunoproteasome function, and thus, antigen presentation machinery in human tumor cells, and how we can modulate the formation of neo-antigens that activate the immune system. I am also focused on the use of aptamer technology for cancer treatment based on iron oxide nanoparticles and, recently, on developing a nanosystem for COVID treatment.
Post-doc Marie-Curie
IBEC
dic 2018
-
mar 2019
Marie Sklodowska-Curie Actions project called Postdoctoral Program in Bioengineering Excellence Scientific Training. Project title: Deciphering the immune-regulating potential of ICAM1-targeted nanocarriers toward an immunotherapeutic application
Post-doc researcher: ARC Fondation
MSC Lab: Paris Diderot Université
oct 2015
-
sep 2018
Granted one of the competitive international postdoctoral scholarship grants from ARC Fondation (France, 3 years postdoc position, PDF20150602405, Project: Smart extracellular microvesicles as biogenic drug delivery system for cancer treatment) I worked on the application of biogenic extracellular vesicles in cancer theranostic as well as in the development of plasmonic nanoparticle-based nanoplatforms for cancer imaging and therapy, at Dr. Florence Gazeau (Laboratoire Matière et Systèmes Compléxes, Paris Diderot University), a pioneer in using extracellular vesicles as therapeutic agents. As a result, 5 publications (including top journals in biomaterials, nanomedicine, & nanotechnology field such as Nanoscale-IF: 6.970-, & Advanced Drug Delivery Review-IP: 15.519) have been published so far (3 as first authors), and 2 others, as the first author, have been submitted. As main achievements, I characterized the formation of stable gold nanoparticle aggregates by polyethyleneimine with therapeutic/imaging potential and demonstrated its anti-tumor efficacy in vivo through photothermia, elucidated the immunological properties of nanoparticle-loaded extracellular vesicles, and demonstrated the therapeutic potential of gold nanoparticle-based 5-FU delivery aggregates for colorectal cancer by combining anti-tumoral drug and photothermia, work associated to the Plan Cancer Network Grant from the National Institute of Cancer (France). In sum, in this period I developed a new gold nanocluster-based therapeutic agent for colorectal carcinoma, proved the convenience of conjugate 5-fluorouracil with gold nanoparticle for colorectal carcinoma treatment, and elucidated the immunological effect of cell-derived extracellular vesicles loaded with magnetic nanoparticles for the future development of immunotherapies.
PhD student
CNB-CSIC
feb 2011
-
jun 2015
In 2011, I started a Ph.D. program (CNB- La Caixa International Ph.D. Program) upon successfully being granted with an international & competitive Ph.D. fellowship in cancer nanotechnology at National Center for Biotechnology, under supervision of Dr. Domingo F Barber Castaño, where I consolidated my research skills applied to the development of new cancer-targeted gene therapy, specifically, magnetic nanoparticle-based gene therapy. As a result, 8 publications (including top journals in biomaterials, nanomedicine, & nanotechnology field such as Biomaterials-IF: 10.273- and Journal of Controlled Release-IF: 7.901) were published from the projects I worked in. As the main achievements, I demonstrated the intrinsic anti-tumor (inhibit migration/invasion), anti-angiogenesis, & pro-inflammatory properties of polyethyleneimine-coated magnetic iron oxide nanoparticles. Altogether, I was a pioneer in demonstrating the intrinsic biological activities of magnetic nanoparticles, specifically those coated with polyethyleneimine, opening the new application in cancer therapy. I successfully presented my doctoral thesis within the Molecular Biosciences program at the Autonomous University of Madrid, with Cum laude grade in 2015. During this time, I participated as a researcher in the following research grants: (1) European project ´´Multifunctional nanotechnology for selective detection and treatment of cancer-MULTIFUN, ref: 262943´; and, (2) Science & Innovation Ministry´s national research grant: ´´Cellular & Molecular Mechanisms behind autoimmune diseases: Identification of new strategies for therapy (SAF2011-23639). I also co-supervised a grade thesis student from the Autonomous University of Madrid during this time. In sum, during my Ph.D. program, I developed a magnetic nanocarrier with intrinsic anti-tumoral, anti-angiogenic, and pro-inflammatory properties all of which have contributed to the current use of these nanocarriers in research grants.
Researcher
Center for Molecular Immunology-Havana (Industry)
sep 2006
-
jul 2010
Graduated from Havana University in 2006 in Biochemistry & Molecular Biology, I have developed abilities in cancer & cancer immunology & immunotherapy, and nanomedicine research throughout my entire work and academic experiences in the past 13 years. During 2005-2006, I worked as a grade student at the Center for Genetic Engineering and Biotechnology (Havana, Cuba) participating in the development of a vaccine against Dengue viruses. Afterward, working in tight relation with clinicians, I was the main responsible for the immune response monitoring of cancer patients enrolled in 1 phase II, 2 phase I, and 1 phase III clinical trials (metastatic breast cancer, melanoma, and head & neck cancer) at Center for Molecular Immunology (CIM)-a pharmaceutical company- within the first 4 years after university, as a research associate. Noteworthy, two of the therapeutic agents assayed in such clinical trials are already approved for human treatment (EGFR-specific monoclonal antibody Nimotuzumab, and EGF-based therapeutic vaccine for lung cancer patients). During this period, I headed for >5 mo. the laboratory I was working at, and organized the First International Workshop on Clinical Cancer Immunotherapy in Havana, November 2009, under the auspices of UICC. I published 4 papers on clinical trial results (2 as a first author) in breast and head & neck cancer patients, proving the efficacy of the very small size proteoliposome (VSSP)-carried N-glycosylated ganglioside antigen as a therapeutic vaccine for metastatic breast cancer and the clinical outcome of using EGFR-specific monoclonal antibody, Nimotuzumab. During this period, I was also a visiting researcher at the Deeley Cancer Research Center in British Columbia, Canada, under supervision of Dr. Brad H. Nelson, upon granted with a UICC Research Travel Fellowship; my worked as visitor scientist was to determine the auto-antibody profile in cancer patients by serological proteome analysis (SEREX). I also successfully supervised a grade thesis student who developed her thesis on immune response elicited by VSSP-carried N-glycosylated ganglioside vaccine in metastatic breast cancer; as a result, one paper has been published on this thesis. In sum, during this period my scientific focus was the study of the immune response of cancer patients enrolled in several clinical trials, contributing to the successful approval of these therapeutic agents for human use (Cuban Drug Agency, EMEA, and FDA).
Formación
PhD
Independent University of Madrid
jul 2012
-
jun 2015
In 2011, I started a Ph.D. program (CNB- La Caixa International Ph.D. Program) upon successfully being granted with an international & competitive Ph.D. fellowship in cancer nanotechnology at National Center for Biotechnology, under supervision of Dr. Domingo F Barber Castaño, where I consolidated my research skills applied to the development of new cancer-targeted gene therapy, specifically, magnetic nanoparticle-based gene therapy. As a result, 8 publications (including top journals in biomaterials, nanomedicine, & nanotechnology field such as Biomaterials-IF: 10.273- and Journal of Controlled Release-IF: 7.901) were published from the projects I worked in.
Master in Science: Molecular and Cellular Biology
Independent University of Madrid
oct 2011
-
jun 2012
Bachelor in Science
Havana University
sep 2001
-
jul 2006
Graduated from Havana University in 2006 in Biochemistry & Molecular Biology
Idiomas
English - C2
French - C1
Italian - B2
Spanish - Native
Otros datos
Reviewer
Ad hoc reviewer (https://publons.com/author/1212641/vladimir-mulens-arias-phd#profile): 2016 (3), 2017 (5), 2018 (22), 2019 (12), and 2020 (13) for Journals: 1.1. International Journal of Nanomedicine (Dove Medical Press, Journal Impact Factor: 4.417) 1.2. Advanced Drugs Delivery Reviews (ELSEVIER, Journal Impact Factor: 13.66) 1.3. RSC Advances (RSC, Journal Impact Factor: 3.049) 1.4. JOVE (MYJoVE Corporation, IF: 1.042) 1.5. Journal of Biomaterials Applications (SAGE, Journal Impact Factor: 2.442) 1.6. Journal of Magnetism and Magnetic Materials (ELSEVIER, Journal Impact Factor: 2.683) 1.7. Journal of Nanobiotechnology ( BioMed Central, Journal Impact Factor: 6.518)
Editorial activity
Editorial activity (https://publons.com/author/1212641/vladimir-mulens-arias-phd#profile): 2.1. Academic Editor for the Journal of Immunology Research (HINDAWI, IP: 3.4), 2020-present. 2.2. Guest Editor for the Journal of Nanobiotechnology (BioMed Central, IP: 6.518) for the special collection: ¨Inorganic nanoparticles and cellular mechanobiology: from nanotoxicology to cytoskeleton-targeting nanotheranostics¨, 2020-present. 2.3. Guest Editor for JoVE (MYJoVE Corporation, IF: 1.042), Methods Collection : ¨Current methodology for probing iron oxide nanoparticle-based theranostics interaction with the immune system: immunotoxicology, adjuvancy, immune cell activation, and immune cell targeting.¨ 2020-present.
Expert committee
External scientific expert committee (Agency, year, and numbers) 3.1. Spanish National Research Agency (2020, 1)
Congress
1. Triggering plasmon coupling of non-infrared (NIR)-invisible gold nanoparticles by three different strategies for cancer theragnosis. Vladimir Mulens Arias et al. International Conference on Nanomaterials Applied to Life Sciences. Type of event: Conference. Type of participation: Oral communication Madrid, Community of Madrid, Spain. 29/01/2020-31/01/2020. IMDEA. 2. Polyethyleneimine as a versatile coating/reducing cationic polymer for metallic nanoparticle-based cancer theranosis. Vladimir Mulens Arias et al. NanoBio&Med 2019. Type of event: Conference. Type of participation: Oral communication Barcelona, Catalonia, Spain. 19/11/2019-11/2019. Institute for Bioengineering pf Catalonia (IBEC) & Phantom Foundation 3. Polyethyleneimine as a versatile coating/reducing cationic polymer for metallic nanoparticle-based cancer theranosis. Vladimir Mulens Arias et al. Spanish Conference on Biomedical Applications of Nanomaterials 2019. Type of event: Conference. Type of participation: Oral communication Madrid, Community of Madrid, Spain. 06/06/2019-06/2019 4. Fractal rearrangement induced by 5-fluorouracil to trigger UV-visible light-absorbent gold nanoparticle plasmon coupling for therapeutic synergy of mild NIR photo- and chemo-therapy in colon carcinoma and carcimatosis treatment. Vladimir Mulens Arias et al. SFNano 2017. Type of event: Conference. Type of participation: Oral communication Bordeaux, France 05/12/2017-12/2017 5. Bio-engineered extracellular microvesicles and cell membrane-derived nanoghosts as multivalent approach for cancer therapy. Vladimir Mulens Arias et al. French Society for Extracellular Vesicles, Annual Meeting 2017. Type of event: Conference. Type of participation: Poster Paris, Île de France, France. 06/11/2017-07/11/2017 6. Magnetically tumor-targeted polyethylenimine-coated superparamagnetic iron oxide nanoparticles impairs tumor vascularization and promotes macrophage infiltration in a mouse model of breast cancer. Vladimir Mulens Arias et al. SEG-SEBD-SEBC Joint Congress 2017. Gijón, Spain. 24/10/2017-27/10/2017 7. Bio-engineered extracellular microvesicles and cell membrane-derived nanoghosts as multivalent approach for cancer therapy. Vladimir Mulens Arias et al. ISEV2017 Annual Meeting. Type of event: Conference. Type of participation: Oral communication Toronto, Canada.18/05/2017-21/05/2017 8. Nanoplasmonic photo-thermal and photo-acoustic conversion and disturbance of adhesome dynamics upon spherical gold nanoparticle uptake by macrophages, fibroblasts, endothelial cells and tumor cells. Vladimir Mulens Arias et al. SFNano 2016. Type of event: Conference. Type of participation: Poster Paris, Île de France, France. 12/12/2016-14/12/2016 9. Effects of polyethylenimine-coated SPIONs on macrophage activation and podosome dynamics. Vladimir Mulens Arias et al. European Congress of Immunology, 2015 Type of event: Conference. Type of participation: Poster. Viena, Austria. 06/09/2015-09/09/2015. ¨
Academic activities
Thesis supervision: 1. Project title: Modified & nanostructured RNAs for regulation og gene expression. (Grade thesis: co-tutor)Entity: Autonomous University of Madrid Student: Ana Belén Latorre Lozano Date of reading: 2014. 2. Project title: NeuGcGM3/VSSP-induced immune response in advanced breast cancer patients. Entity: Havana University Student: Anet Valdes Zayas Date of reading: 11/06/2010
Fellowships
- La Caixa International PhD Program 2009. Granted. - ARC Fondation, Individual Postdoctoral Research Scholarship (research project). Granted. - Marie Skladowska-Curie Actions project Postdoctoral Program in Bioengineering Excellence Scientific Training ( BEST) at IBEC (research project). Granted. - Juan de la Cierva-Incorporación 2018. Granted.
Participation in R&D and Innovation projects
1 Preclinical validation of a MNK1-specific aptamer formulation in breast cancer therapy (DTS18/000121). (Carlos III Health Institute, Research Project son Health, Technological Development in Health modality. & CNB (CSIC)). 01/01/2019-31/12/2020. 94.600 €. Team member. 2 Understanding the action mechanism and biodegradation of nanomedicines based on nanoparticles for anti-tumoral therapy optimization (SAF2017-82223-R). Ministerio de Economía, Industria y Competitividad. Plan Estatal I+D+i.. (National Center for Biotechnology (CSIC)). 01/01/2018-31/12/2020. Team member. 3 Network on Bioapplications of nanoparticles (MAT2016-81955-REDT) (National Center for Biotechnology (CSIC)). 02/01/2017-31/12/2019. Team member. 4 Extracellular vescicles as nanonarriers for cancer treatment Vladimir Mulens Arias. (CNRS & ARC Fondation). 01/10/2015-28/09/2018. Co-Principal Investigator. 5 European project: “Multifunctional Nanotechnology for selective detection and Treatment of cancer (MULTIFUN)” (Ref: 262943). European Comission, FP7-NMP-2010-LARGE-4, Programme “Theme 4 – NMP - Nanosciences, Nanotechnologies, Materials and new Production Technologies”.. Domingo F Barber Castaño. (National Center for Biotechnology). 13/06/2011-12/06/2015. 250.000 €. Team member. 6 Cellular & Molecular Mechanisms behind autoimmune diseases:Identification of new strategies for therapy (SAF2011-23639). Ministerio de Ciencia e Innovación. Plan Nacional I+D+i. Domingo F Barber Castaño. (National Center for Biotechnology). 01/01/2012- 31/12/2014. 229.900 €. Team member. 7 Inflammation & Rheumatic diseases Research Network (RIER) (nº expediente: RD08/0075/0015) Instituto de Salud Carlos III, Plan Nacional de I+D+i 2008-2011 Subprograma RETICS (Redes Temáticas de Investigación Cooperativa en Salud).. Domingo F Barber Castaño. (National Center for Biotechnology). 01/01/2009- 31/12/2012. 82.613,82 €. Team member. 8 Cellular & Molecular Mechanisms thet regulate the onset and progression of Autoimmune & Inflammatory Diseases (SAF2008-00471) Ministerio de Ciencia e Innovación. Plan Nacional I+D+i. Domingo F Barber Castaño. (National Center for Biotechnology). 01/01/2009-31/12/2011. 229.900 €. Team member. 9 Anti-tumoral effect of a NeuGcGM3-based vaccine in Breast cancer patients (Clinical trials I/II and III) CITMA. Luis Enriquez Fernández. (Center for Molecular Immunology). 04/09/2006-31/07/2010. Team member. 10 Deciphering the immune-regulating potential of ICAM-1-targeted nanocarriers toward an immunotherapeutic application Vladimir Mulens Arias. (Institute for Bioengineering of Catalonia). From 01/12/2018. Co-Principal Investigator.
Publications
1 (Scientific paper: Quartile 1). Vladimir Mulens-Arias, Alba Nicolás-Boluda, Amandine Pinto, Alice Balfourier, Amanda K Andriola Silva, Florent Carn, Marc Pocard and Florence Gazeau. Tumor-selective mild hyperthermia associated to chemotherapy in colon peritoneal carcinomatosis by photoactivation of fluorouracil-gold nanoparticles complexes (1st out of 8). ACS Nano 2020 (Accepted 01/2021) IF 14.588 2 (Scientific paper: Quartile 1). Vladimir Mulens-Arias, Alice Balfourier, Alba Nicolás-Boluda, Florent Carn, and Florence Gazeau. Endocytosis-driven gold nanoparticle fractal rearrangement and its influence on photothermal conversion. (1st out of 5). Nanoscale, 2020 (1st round: Submitted 30/05/2020) IF 8.758 3 (Scientific paper: Quartile 1). Alice Balfourier, Vladimir Mulens-Arias, Florence Gazeau, and Florent Carn. Rational Design of Fractal Gold Nanosphere Assemblies with Optimized Photothermal Conversion. (2nd out of 4). Journal of Physical Chemistry C, 31/03/2020. DOI: 10.1021/acs.jpcc.0c00384. IF 4.189 4 (Scientific paper: Quartile 1). Vladimir Mulens Arias, José M Rojas; Laura Sanz-Ortega; Yadileiny Portilla; Sonia Pérez-Yague; Domingo F Barber Castaño. Polyethylenimine-coated superparamagnetic iron oxide nanoparticles impair in vitro and in vivo angiogenesis. (1st out of 6). Nanomedicine: Nanotechnology, Biology, and Medicine. 2019. Polyethylenimine-coated superparamagnetic iron oxide nanoparticles impair in vitro and in vivo angiogenesis Nanomedicine: Nanotechnology, Biology, and Medicine. DOI: 10.1016/j.nano.2019.102063. IF 5.57 5 (Scientific paper: Quartile 1). Vladimir Mulens Arias, Alba Nicolás Boluda; Alexandre Gehanno; Alice Balfourier; Florent Carn; Florence Gazeau. (1st out of 6). 2019. Polyethyleneimine-assisted one-pot synthesis of quasi-fractal plasmonic gold nanocomposites as a photothermal theranostic agent. Nanoscale. 1, pp.3344-3359. DOI: 10.1039/C8NR09849B. IF 6.895 6 (Scientific paper: Quartile 1). Vladimir Mulens-Arias, Alice Balfourier; Alba Nicolás-Boluda; Florent Carn; Florence Gazeau. (1st out of 5). 2018. Disturbance of adhesomes by gold nanoparticles reveals a size- and cell type-bias Biomaterials Science. DOI:10.1039/C. IF 6.183 7 (Scientific paper: Quartile 1). Vladimir Mulens Arias, Alba Nicolás Boluda; Amanda K Andriola Silva; Florence Gazeau. (1st out of 5). 2018. Theranostic Iron Oxide Nanoparticle Cargo Defines Extracellular Vesicle-Dependent Modulation of Macrophage Activation and Migratory Behavior Advanced Biosystems. DOI: 10.1002/adbi.201800079. IF 3.526 8 (Scientific paper: Quartile 1). Anet Valdes-Zayas, Zuyen González; Vladimir Mulens; Aliz M. Vega; Kirenia Pérez; Patricia Lorenzo-Luaces; María C. Rubio; Anabely Estevez; Idelmis Curbelo; Luis E. Fernández; Tania Crombet; Zaima Mazorra. (3rd out of 12). 2017. Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy. Journal of Immunotherapy. 40-8, pp.289-301. DOI: 10.1097/CJI.0000000000000175. IF 4.059 9 (Scientific paper : Quartile 1). José M. Rojas; Roberto Spada; Laura Morillas; Raquel Mejías; Vladimir Mulens-Arias; Sonia Pérez-Yague; Domingo F. Barber. (5th out of 7). 2016. PI3K p85 regulatory subunit deficiency does not affect NK cell differentiation and increases NKG2D-mediated activation Journal of Leukocyte Biology. Society for Leukocyte Biology. 100-6, pp.1285-1296. DOI: 10.1189/jlb.1A1215-541RR. IF 3.757 10 (Scientific paper : Quartile 1). José M. Rojas; Laura Sanz-Ortega; Vladimir Mulens-Arias; Lucía Gutiérrez; Sonia Pérez-Yague; Domingo F. Barber. (3rd out of 6). 2015. Superparamagnetic iron oxide nanoparticle uptake alters M2 macrophage phenotype, iron metabolism, migration and invasion Nanomedicine: Nanotechnology, Biology, and Medicine. 12, pp.1127-1138. DOI: 10.1016/j.nano.2015.11.020. IF 5.57 11 (Scientific paper: Quartile 1). Vladimir Mulens-Arias; José M. Rojas; Sonia Pérez-Yague; María del Puerto Morales; Domingo F. Barber. (1st out of 5). 2015. Polyethylenimine-coated SPION exhibits potential intrinsic anti-metastatic properties inhibiting migration and invasion of pancreatic tumor cells Journal of Controlled Release.. 216, pp.78-92. DOI: 10.1016/j.jconrel.2015.08.009. IF 7.727 12 (Scientific paper: Quartile 1). Vladimir Mulens-Arias; José M. Rojas; Sonia Pérez-Yague; María del Puerto Morales; Domingo F. Barber. (1st out of 5). 2015. Polyethylenimine-coated SPIONs trigger macrophage activation through TLR-4 signaling and ROS production and modulate podosome dynamics Biomaterials. 52, pp.494-506. DOI: 10.1016/j.biomaterials.2015.02.068. IF 10.317 13 (Scientific paper: Quartile 1). Roberto Spada; José M. Rojas; Sonia Pérez-Yague; Vladimir Mulens; Pablo Cannata-Ortiz; Rafael Bragado; Domingo F. Barber. (4th out of 7). 2014. NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery Journal of Leukocyte Biology. Society for Leukocyte Biology. 97-3, pp.583-598. DOI: 10.1189/jlb.4A0714-326R. IF 3.757 14 (Scientific paper: Quartile 1). Teresa M. Zotes; Roberto Spada; Vladimir Mulens; Sonia Pérez-Yague; Carlos Sorzano; Klaus Okkenhaug; Ana C. Carrera; Domingo F. Barber. (3rd out of 8). 2013. PI3K p110g is expressed by gp38(-)CD31(+) and gp38(+)CD31(+) spleen stromal cells and regulates their CCL19, CCL21, and LT?R mRNA levels PLoS One. 8-8. DOI: 10.1371/journal.pone.0072960. IF 2.875 15 (Scientific paper: Quartile 1). Marta Osorio Rodríguez; Teresa Cruz Rivero; Ramón del Castillo Bahi; Carlos Roca Muchuli; Miguel Azcue Bilbao; Elia Neninger Vinageras; José Alert; Julio Jiménez Galainena; Edmundo Rodríguez; Elías Gracia; Bárbara Mulén; Bárbara Wilkinson; Esther Lucía de Armas; Kirenia Pérez; Idael Pineda; Milagros Frómeta; Idrissa Leonard; Vladimir Mulens; Carmen Viada; Patricia Luaces; Olga Torres; Normando Iznaga; Tania Crombet.. (18th out of 23). 2010. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck Cancer Biology and Therapy. 9-5, pp.343-349. DOI: 10.4161/cbt.9.5.10981. IF 3.336 16 (Scientific paper: Quartile 1). Vladimir Mulens; Ana de la Torre; Patricia Marinello; Ronald Rodríguez; Jorge Cardoso; René Díaz; Miguel O'Farril; Amparo Macías; Carmen Viada; Giselle Suárez; Adriana Carr; Tania Crombet; Zaima Mazorra; Rolando Pérez; Luis E. Fernández. (1st out of 15). 2009. Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients Human Vaccine. 6-9, pp.736-744. DOI: 10.4161/hv.6.9.12571. IF 3.059 17 (Review paper: Quartile 1). Vladimir Mulens-Arias; José Manuel Rojas Carrasco; Domingo F Barber. (1st out of 3). 2020. The intrinsic biological identities of iron oxide nanoparticles and their coatings: Unexplored territory for combinatorial therapies. Nanomaterials, 10(5), 837. MDPI. DOI: 10.3390/nano10050837. IF 4.324 18 (Review paper: Quartile 1). Max Piffoux; Alba Nicolás-Boluda; Vladimir Mulens-Arias; Sophie Richard; Gabriel Rahmi; Florence Gazeau; Claire Wilhelm; Amanda A.K. Silva. (3rd out of 8). 2018. Extracellular vesicles for personalized medicine: the input of physically triggered production, loading and theranostic properties Advanced Drug Delivery Reviews. DOI: 10.1016/j.addr.2018.12.009. IF 13.3 19 (Review paper). Vladimir Mulens; María del Puerto Morales; Domingo F. Barber. (1st out of 3). 2013. Development of Magnetic Nanoparticles for Cancer Gene Therapy: A Comprehensive Review. International Scholarly Research Notices (ISRN Nanomaterials). Hindawi. 2013, pp.1-14. DOI: 10.1155/2013/646284 20 (Review paper). Vladimir Mulens-Arias; Patricia Marinello; Adriana Carr; Zaima Mazorra; Luis E. Fernández. (1st out of 5). 2009. Gangliosides in Cancer Biology & Immunotherapy: The Cuban Experience Cancerología. Revista del Instituto Nacional de Cancerología, México. 4-3, pp.155-167.
Currículums relacionados
